Vienva
Generic: LEVONORGESTREL AND ETHINYL ESTRADIOL
Basic Information
Manufacturer
Xiromed, LLC.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
FDA Set ID
58ea31df-f9cf-7d00-c2db-0529fb9a3e53
Indications & Usage
INDICATIONS AND USAGE Vienva (levonorgestrel and ethinyl estradiol tablets, USP) is indicated for use by females of reproductive potential to prevent pregnancy.
Limitations of use : The efficacy of levonorgestrel and ethinyl estradiol in women with a body mass index (BMI) of > 35 kg/m 2 has not been adequately evaluated.
In a clinical trial with levonorgestrel and ethinyl estradiol tablets, 1,477 subjects had 7,720 cycles of use and a total of 5 pregnancies were reported.
This represents an overall pregnancy rate of 0.84 per 100 woman-years.
This rate includes patients who did not take the drug correctly.
One or more pills were missed during 1,479 (18.8%) of the 7,870 cycles; thus all tablets were taken during 6,391 (81.2%) of the 7,870 cycles.
Of the total 7,870 cycles, a total of 150 cycles were excluded from the calculation of the Pearl index due to the use of backup contraception and/or missing 3 or more consecutive pills.
The mean BMI of the study population was 24 kg/m 2 .
Females with a BMI greater than 30 kg/m 2 accounted for 12.1% (n=179) of the study population.
Females with a BMI over 35 kg/m 2 accounted for 4.3% (n=63) of the study population.
Limitations of use : The efficacy of levonorgestrel and ethinyl estradiol in women with a body mass index (BMI) of > 35 kg/m 2 has not been adequately evaluated.
In a clinical trial with levonorgestrel and ethinyl estradiol tablets, 1,477 subjects had 7,720 cycles of use and a total of 5 pregnancies were reported.
This represents an overall pregnancy rate of 0.84 per 100 woman-years.
This rate includes patients who did not take the drug correctly.
One or more pills were missed during 1,479 (18.8%) of the 7,870 cycles; thus all tablets were taken during 6,391 (81.2%) of the 7,870 cycles.
Of the total 7,870 cycles, a total of 150 cycles were excluded from the calculation of the Pearl index due to the use of backup contraception and/or missing 3 or more consecutive pills.
The mean BMI of the study population was 24 kg/m 2 .
Females with a BMI greater than 30 kg/m 2 accounted for 12.1% (n=179) of the study population.
Females with a BMI over 35 kg/m 2 accounted for 4.3% (n=63) of the study population.
Warnings
WARNINGS WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptives (COC) use.
This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked.
For this reason, COCs, including levonorgestrel and ethinyl estradiol, are contraindicated in women who are over 35 years of age and smoke.
The use of oral contraceptives is associated with increased risks of several serious conditions including venous and arterial thrombotic and thromboembolic events (such as myocardial infarction, thromboembolism, and stroke), hepatic neoplasia, gallbladder disease, and hypertension, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors.
The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as certain inherited or acquired thrombophilias, hypertension, hyperlipidemias, obesity, diabetes, and surgery or trauma with increased risk of thrombosis (see CONTRAINDICATIONS ).
Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.
The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher doses of estrogens and progestogens than those in common use today.
The effect of long-term use of the oral contraceptives with lower doses of both estrogens and progestogens remains to be determined.
Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies.
Case control studies provide a measure of the relative risk of disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers.
The relative risk does not provide information on the actual clinical occurrence of a disease.
Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral-contraceptive users and nonusers.
The attributable risk does provide information about the actual occurrence of a disease in the population.
For further information, the reader is referred to a text on epidemiological methods.
1.
Thromboembolic Disorders and Other Vascular Problems Cardiovascular and Cerebrovascular Events Use of CHCs increases the risk of cardiovascular events and cerebrovascular events, such as myocardial infarction and stroke.
The risk of these events with CHC use is greater in females with concomitant risk factors: age 35 years and older, smoking, hypertension, dyslipidemia, diabetes, or obesity.
The risk increases with increasing age and with increasing number of cigarettes smoked.
Venous Thromboembolism Use of CHCs also increases the risk of VTE, such as deep vein thrombosis and pulmonary embolism.
The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman-years.
The VTE risk should be considered in the context of relevant subpopulations of females of reproductive potential who are not taking CHCs (see ADVERSE REACTIONS ).
Risk factors for VTE with CHC use include smoking, obesity, family history of VTE, and prolonged immobilization, in addition to other factors that contraindicate use of CHCs (see CONTRAINDICATIONS ).
The presence of multiple risk factors for VTE with CHC use may further increase the risk.
The risk of VTE is highest during the first year of CHC use and when restarting hormonal contraception after a break of four weeks or longer.
The risk of VTE returns to baseline approximately 3 months after CHC use is discontinued.
Postpartum Venous Thromboembolism The risk of VTE is increased during the first six weeks postpartum.
The risk is highest up to four weeks postpartum but remains higher than baseline until at least six weeks postpartum.
The presence of multiple risk factors for VTE may further increase the risk.
Obstetric complications may extend the elevated risk up to 12 weeks postpartum.
2.
Malignant Neoplasms Breast Cancer Levonorgestrel and ethinyl estradiol is contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS ).
Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk.
Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer.
However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE REACTIONS ).
Cervical Cancer Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia or invasive cervical cancer in some populations of women.
However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.
3.
Hepatic Neoplasia Benign hepatic adenomas are associated with oral-contraceptive use, although the incidence of these benign tumors is rare in the United States.
Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use.
Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage.
Studies from Britain have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) oral-contraceptive users.
However, these cancers are extremely rare in the U.S.
and the attributable risk (the excess incidence) of liver cancers in oral-contraceptive users approaches less than one per million users.
4.
Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs.
Discontinue levonorgestrel and ethinyl estradiol prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see CONTRAINDICATIONS ).
Levonorgestrel and ethinyl estradiol can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen.
5.
Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives that may lead to partial or complete loss of vision.
Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.
Appropriate diagnostic and therapeutic measures should be undertaken immediately.
6.
Oral-Contraceptive Use Before or During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in infants born to women who have used oral contraceptives prior to pregnancy.
Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb-reduction defects are concerned, when taken inadvertently during early pregnancy (see CONTRAINDICATIONS ).
It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out.
If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period.
Oral-contraceptive use should be discontinued if pregnancy is confirmed.
7.
Gallbladder Disease Combination oral contraceptives may worsen existing gallbladder disease and may accelerate the development of this disease in previously asymptomatic women.
Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens.
More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral-contraceptive users may be minimal.
The recent findings of minimal risk may be related to the use of oral-contraceptive formulations containing lower hormonal doses of estrogens and progestogens.
8.
Carbohydrate and Lipid Metabolic Effects Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users.
Carefully monitor females with prediabetes and diabetes who are using levonorgestrel and ethinyl estradiol.
Levonorgestrel and ethinyl estradiol may decrease glucose tolerance.
A small proportion of women will have persistent hypertriglyceridemia while on COCs.
As discussed earlier (see WARNINGS and PRECAUTIONS ), changes in serum triglycerides and lipoprotein levels have been reported in oral-contraceptive users.
9.
Elevated Blood Pressure Levonorgestrel and ethinyl estradiol is contraindicated in women with uncontrolled hypertension or hypertension with vascular disease (see CONTRAINDICATIONS ).
For all females, including those with well-controlled hypertension, monitor blood pressure at routine visits and stop levonorgestrel and ethinyl estradiol if blood pressure rises significantly.
An increase in blood pressure has been reported in females using CHCs, and this increase is more likely in older women with extended duration of use.
The effect of CHCs on blood pressure may vary according to the progestin in the CHC.
10.
Headache Levonorgestrel and ethinyl estradiol is contraindicated in females who have headaches with focal neurological symptoms or have migraine headaches with aura, and in women over age 35 years who have migraine head aches with or without aura.
The onset or exacerbation of migraine or development of headache with a new pattern that is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.
Consider discontinuation of levonorgestrel and ethinyl estradiol if there is an increased frequency or severity of migraines during CHC use (which may be prodromal of a cerebrovascular event; see WARNINGS and CONTRAINDICATIONS .) 11.
Bleeding Irregularities Unscheduled bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use.
The type and dose of progestogen may be important.
If bleeding persists or recurs, nonhormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of unscheduled bleeding, as in the case of any abnormal vaginal bleeding.
If pathology has been excluded, time or a change to another formulation may solve the problem.
In the event of amenorrhea, pregnancy should be ruled out.
Some women may encounter post-pill amenorrhea or oligomenorrhea (possibly with anovulation), especially when such a condition was preexistent.
In the clinical trial with levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg tablets, unscheduled bleeding was defined as bleeding or spotting that occurred: During cycle 1 on pill-pack Days 4 to 21, inclusive of a 28-day cycle.
In subsequent cycles, on Days 5 to 21 inclusive or on pill-pack Days 1 to 4 inclusive if preceded by 2 consecutive days without bleeding or spotting.
Based on subject diaries, the proportion of subjects reporting unscheduled bleeding or spotting per 28-day cycle decreased over time: 30.5% at Cycle 1 versus 18.2% at Cycle 12.
12.
Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.
13.
Chloasma Chloasma may occur, especially in women with a history of chloasma gravidarum.
Advise women with a history of chloasma to avoid exposure to the sun or ultraviolet radiation while taking levonorgestrel and ethinyl estradiol .
14.
Effect on Binding Globulins The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin.
Monitor thyroid-stimulating hormone (TSH) levels for females receiving levonorgestrel and ethinyl estradiol and thyroid hormone replacement therapy concomitantly.
Follow the recommendation for the thyroid hormone in accordance with its Prescribing Information.
This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked.
For this reason, COCs, including levonorgestrel and ethinyl estradiol, are contraindicated in women who are over 35 years of age and smoke.
The use of oral contraceptives is associated with increased risks of several serious conditions including venous and arterial thrombotic and thromboembolic events (such as myocardial infarction, thromboembolism, and stroke), hepatic neoplasia, gallbladder disease, and hypertension, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors.
The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as certain inherited or acquired thrombophilias, hypertension, hyperlipidemias, obesity, diabetes, and surgery or trauma with increased risk of thrombosis (see CONTRAINDICATIONS ).
Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.
The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher doses of estrogens and progestogens than those in common use today.
The effect of long-term use of the oral contraceptives with lower doses of both estrogens and progestogens remains to be determined.
Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies.
Case control studies provide a measure of the relative risk of disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers.
The relative risk does not provide information on the actual clinical occurrence of a disease.
Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral-contraceptive users and nonusers.
The attributable risk does provide information about the actual occurrence of a disease in the population.
For further information, the reader is referred to a text on epidemiological methods.
1.
Thromboembolic Disorders and Other Vascular Problems Cardiovascular and Cerebrovascular Events Use of CHCs increases the risk of cardiovascular events and cerebrovascular events, such as myocardial infarction and stroke.
The risk of these events with CHC use is greater in females with concomitant risk factors: age 35 years and older, smoking, hypertension, dyslipidemia, diabetes, or obesity.
The risk increases with increasing age and with increasing number of cigarettes smoked.
Venous Thromboembolism Use of CHCs also increases the risk of VTE, such as deep vein thrombosis and pulmonary embolism.
The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman-years.
The VTE risk should be considered in the context of relevant subpopulations of females of reproductive potential who are not taking CHCs (see ADVERSE REACTIONS ).
Risk factors for VTE with CHC use include smoking, obesity, family history of VTE, and prolonged immobilization, in addition to other factors that contraindicate use of CHCs (see CONTRAINDICATIONS ).
The presence of multiple risk factors for VTE with CHC use may further increase the risk.
The risk of VTE is highest during the first year of CHC use and when restarting hormonal contraception after a break of four weeks or longer.
The risk of VTE returns to baseline approximately 3 months after CHC use is discontinued.
Postpartum Venous Thromboembolism The risk of VTE is increased during the first six weeks postpartum.
The risk is highest up to four weeks postpartum but remains higher than baseline until at least six weeks postpartum.
The presence of multiple risk factors for VTE may further increase the risk.
Obstetric complications may extend the elevated risk up to 12 weeks postpartum.
2.
Malignant Neoplasms Breast Cancer Levonorgestrel and ethinyl estradiol is contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive (see CONTRAINDICATIONS ).
Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk.
Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer.
However, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of COC use (see ADVERSE REACTIONS ).
Cervical Cancer Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia or invasive cervical cancer in some populations of women.
However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.
3.
Hepatic Neoplasia Benign hepatic adenomas are associated with oral-contraceptive use, although the incidence of these benign tumors is rare in the United States.
Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use.
Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage.
Studies from Britain have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) oral-contraceptive users.
However, these cancers are extremely rare in the U.S.
and the attributable risk (the excess incidence) of liver cancers in oral-contraceptive users approaches less than one per million users.
4.
Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs.
Discontinue levonorgestrel and ethinyl estradiol prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (see CONTRAINDICATIONS ).
Levonorgestrel and ethinyl estradiol can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen.
5.
Ocular Lesions There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives that may lead to partial or complete loss of vision.
Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.
Appropriate diagnostic and therapeutic measures should be undertaken immediately.
6.
Oral-Contraceptive Use Before or During Early Pregnancy Extensive epidemiological studies have revealed no increased risk of birth defects in infants born to women who have used oral contraceptives prior to pregnancy.
Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb-reduction defects are concerned, when taken inadvertently during early pregnancy (see CONTRAINDICATIONS ).
It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out.
If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period.
Oral-contraceptive use should be discontinued if pregnancy is confirmed.
7.
Gallbladder Disease Combination oral contraceptives may worsen existing gallbladder disease and may accelerate the development of this disease in previously asymptomatic women.
Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens.
More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral-contraceptive users may be minimal.
The recent findings of minimal risk may be related to the use of oral-contraceptive formulations containing lower hormonal doses of estrogens and progestogens.
8.
Carbohydrate and Lipid Metabolic Effects Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users.
Carefully monitor females with prediabetes and diabetes who are using levonorgestrel and ethinyl estradiol.
Levonorgestrel and ethinyl estradiol may decrease glucose tolerance.
A small proportion of women will have persistent hypertriglyceridemia while on COCs.
As discussed earlier (see WARNINGS and PRECAUTIONS ), changes in serum triglycerides and lipoprotein levels have been reported in oral-contraceptive users.
9.
Elevated Blood Pressure Levonorgestrel and ethinyl estradiol is contraindicated in women with uncontrolled hypertension or hypertension with vascular disease (see CONTRAINDICATIONS ).
For all females, including those with well-controlled hypertension, monitor blood pressure at routine visits and stop levonorgestrel and ethinyl estradiol if blood pressure rises significantly.
An increase in blood pressure has been reported in females using CHCs, and this increase is more likely in older women with extended duration of use.
The effect of CHCs on blood pressure may vary according to the progestin in the CHC.
10.
Headache Levonorgestrel and ethinyl estradiol is contraindicated in females who have headaches with focal neurological symptoms or have migraine headaches with aura, and in women over age 35 years who have migraine head aches with or without aura.
The onset or exacerbation of migraine or development of headache with a new pattern that is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.
Consider discontinuation of levonorgestrel and ethinyl estradiol if there is an increased frequency or severity of migraines during CHC use (which may be prodromal of a cerebrovascular event; see WARNINGS and CONTRAINDICATIONS .) 11.
Bleeding Irregularities Unscheduled bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use.
The type and dose of progestogen may be important.
If bleeding persists or recurs, nonhormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of unscheduled bleeding, as in the case of any abnormal vaginal bleeding.
If pathology has been excluded, time or a change to another formulation may solve the problem.
In the event of amenorrhea, pregnancy should be ruled out.
Some women may encounter post-pill amenorrhea or oligomenorrhea (possibly with anovulation), especially when such a condition was preexistent.
In the clinical trial with levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg tablets, unscheduled bleeding was defined as bleeding or spotting that occurred: During cycle 1 on pill-pack Days 4 to 21, inclusive of a 28-day cycle.
In subsequent cycles, on Days 5 to 21 inclusive or on pill-pack Days 1 to 4 inclusive if preceded by 2 consecutive days without bleeding or spotting.
Based on subject diaries, the proportion of subjects reporting unscheduled bleeding or spotting per 28-day cycle decreased over time: 30.5% at Cycle 1 versus 18.2% at Cycle 12.
12.
Hereditary Angioedema In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.
13.
Chloasma Chloasma may occur, especially in women with a history of chloasma gravidarum.
Advise women with a history of chloasma to avoid exposure to the sun or ultraviolet radiation while taking levonorgestrel and ethinyl estradiol .
14.
Effect on Binding Globulins The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin.
Monitor thyroid-stimulating hormone (TSH) levels for females receiving levonorgestrel and ethinyl estradiol and thyroid hormone replacement therapy concomitantly.
Follow the recommendation for the thyroid hormone in accordance with its Prescribing Information.
Adverse Reactions
ADVERSE REACTIONS An increased risk of the following serious adverse reactions (see WARNINGS section for additional information) has been associated with the use of oral contraceptives: Thromboembolic and thrombotic disorders and other vascular problems (including thrombophlebitis and venous thrombosis with or without pulmonary embolism, mesenteric thrombosis, arterial thromboembolism, myocardial infarction, cerebral hemorrhage, cerebral thrombosis), carcinoma of the reproductive organs and breasts, hepatic neoplasia (including hepatic adenomas or benign liver tumors), ocular lesions (including retinal vascular thrombosis), gallbladder disease, carbohydrate and lipid effects, elevated blood pressure, and headache including migraine.
Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 2).
Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 2).
One of these studies reported no association between breast cancer risk and COC use.
The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use.
Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use.
Figure 2: Risk of Breast Cancer with Combined Oral Contraceptives RR = relative risk; OR = odds ratio; HR = hazard ratio.
“ever COC” are females with current or past COC use; “never COC use” are females that never used COCs The following adverse reactions associated with the use of oral CHCs were identified in clinical studies or postmarketing reports.
Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Common adverse reactions associated with oral CHCs are headache, abdominal pain, nausea, metrorrhagia, vaginal moniliasis and pain, acne, and vaginitis.
Additional adverse reactions that have been reported include the following: Eye disorder: intolerance to contact lenses, steepening of corneal curvature Gastrointestinal disorders: Abdominal bloating, vomiting General disorders and administration site conditions: Edema, fluid retention Hepatobiliary disorders: Cholestatic jaundice Pyschiatric disorders: Change in libido, mood changes Reproductive system and breast disorders: Amenorrhea, breast tenderness, breast pain, breast enlargement, increased cervical mucous, change in menstrual flow, unscheduled bleeding Skin and subcutaneous tissue disorders: Acne, melasma Vascular disorders: Budd-Chiari syndrome, aggravation of varicose veins
Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 2).
Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 2).
One of these studies reported no association between breast cancer risk and COC use.
The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use.
Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use.
Figure 2: Risk of Breast Cancer with Combined Oral Contraceptives RR = relative risk; OR = odds ratio; HR = hazard ratio.
“ever COC” are females with current or past COC use; “never COC use” are females that never used COCs The following adverse reactions associated with the use of oral CHCs were identified in clinical studies or postmarketing reports.
Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Common adverse reactions associated with oral CHCs are headache, abdominal pain, nausea, metrorrhagia, vaginal moniliasis and pain, acne, and vaginitis.
Additional adverse reactions that have been reported include the following: Eye disorder: intolerance to contact lenses, steepening of corneal curvature Gastrointestinal disorders: Abdominal bloating, vomiting General disorders and administration site conditions: Edema, fluid retention Hepatobiliary disorders: Cholestatic jaundice Pyschiatric disorders: Change in libido, mood changes Reproductive system and breast disorders: Amenorrhea, breast tenderness, breast pain, breast enlargement, increased cervical mucous, change in menstrual flow, unscheduled bleeding Skin and subcutaneous tissue disorders: Acne, melasma Vascular disorders: Budd-Chiari syndrome, aggravation of varicose veins